Global Drug Delivery Partnering Deals Report 2014-2020: Access to 1,000+ Deal Records Sorted by Company A-Z, Stage of Development, Deal Type, Therapy Focus, and Technology Type
DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Drug Delivery Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides details of the latest Drug Delivery agreements announced in the life sciences since 2014.
-- Trends in Drug Delivery dealmaking in the biopharma industry since 2014
-- Analysis of Drug Delivery deal structure
-- Access to headline, upfront, milestone and royalty data
-- Case studies of real-life Drug Delivery deals
-- Access to Drug Delivery contract documents
-- Leading Drug Delivery deals by value since 2014
-- Most active Drug Delivery dealmakers since 2014
The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.
The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1,000 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Drug Delivery dealmaking.
-- Chapter 1 provides an introduction to the report.
-- Chapter 2 provides an overview of the trends in Drug Delivery dealmaking
since 2014, including details of headline, upfront, milestone and
royalty terms.
-- Chapter 3 provides a review of the leading Drug Delivery deals since
2014. Deals are listed by headline value. Where the deal has an
agreement contract published at the SEC a link provides online access to
the contract.
-- Chapter 4 provides a comprehensive listing of the top 25 most active
companies in Drug Delivery dealmaking with a brief summary followed by a
comprehensive listing of Drug Delivery deals announced by that company,
as well as contract documents, where available.
-- Chapter 5 provides a comprehensive and detailed review of Drug Delivery
partnering deals signed and announced since Jan 2014, where a contract
document is available in the public domain. Each deal title links via
Weblink to an online version of the deal record and contract document,
providing easy access to each contract document on demand.
-- Chapter 6 provides a comprehensive and detailed review of Drug Delivery
partnering deals signed and announced since Jan 2014. The Chapter is
organized by specific Drug Delivery technology type. Each deal title
links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each deal on
demand.
A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.
Analyzing actual contract agreements allows assessment of the following:
-- What are the precise rights granted or optioned?
-- What is actually granted by the agreement to the partner company?
-- What exclusivity is granted?
-- What is the payment structure for the deal?
-- How are sales and payments audited?
-- What is the deal term?
-- How are the key terms of the agreement defined?
-- How are IPRs handled and owned?
-- Who is responsible for commercialization?
-- Who is responsible for development, supply, and manufacture?
-- How is confidentiality and publication managed?
-- How are disputes to be resolved?
-- Under what conditions can the deal be terminated?
-- What happens when there is a change of ownership?
-- What sublicensing and subcontracting provisions have been agreed?
-- Which boilerplate clauses does the company insist upon?
-- Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
-- Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
-- 3DMed
-- 3M Drug Delivery Systems
-- 3P Biopharmaceuticals
-- 3PrimeDx
-- 3SBio
-- A*STAR Agency for Science
-- Technology and Research
-- A1 Group
-- AADi
-- Abbott Laboratories
-- Abbvie
-- Abiogen Pharma
-- Absorption Systems
-- Accelis Pharma
-- Accord Healthcare
-- Acella Pharmaceuticals
-- Acelrx Pharmaceuticals
-- Acerus
-- Aceto Corporation
-- Ache
-- Aclaris Therapeutics
-- Acorda Therapeutics
-- Actavis (acquired by Watson)
-- Actavis (name changed to Allergan)
-- Actelion
-- Acuity Pharmaceuticals
-- Acura Pharmaceuticals
-- AdAlta
-- Adama
-- Adamas Pharmaceuticals
-- Adamis Pharmaceuticals
-- Adaptive Health
-- Adapt Pharma
-- Adare Pharmaceuticals
-- Adhesys Medical
-- Adhezion Biomedical
-- Advanced Catheter Therapies
-- Advanced Cooling Therapy
-- Advanced Dosage Forms
-- Advanced Medical Solutions
-- Advaxis
-- Adverum Biotechnologies
-- Aegis Therapeutics
-- Aequus Pharmaceuticals
-- Aerie Pharmaceuticals
-- Aerogen
-- Aero Pump
-- AEterna Zentaris
-- Afaxys Pharmaceuticals
-- AFT Pharmaceuticals
-- Agalimmune
-- Aires Pharmaceuticals
-- AIT Therapeutics
-- Ajad Medical
-- Akorn
-- Akrivis Technologies
-- Albany Molecular Research
-- Albion
-- Albumedix
-- Alcyone Lifesciences
-- Alexion Pharmaceuticals
-- Alexza Pharmaceuticals
-- Alfa Wassermann
-- Aligo
-- Alimera Sciences
-- ALK-Abello
-- Allergan
-- Alliance for Lupus Research
-- AllianceRx Walgreens Prime
-- Allogene Therapeutics
-- AlloSource
-- Almirall
-- Alnylam Pharmaceuticals
-- Alphamab
-- ALRISE Biosystems
-- ALS Association
-- Altum Pharmaceuticals
-- Altus Formulation
-- Aluna
-- Alvit LCS Pharma
-- Alvogen
-- Alzyn
-- Amarantus BioSciences
-- Amedica
-- American CryoStem
-- American Diabetes Association
-- Amerigen Pharmaceuticals
-- Amerinet
-- AmerisourceBergen
-- Amgen
-- AMI
-- AMPEL BioSolutions
-- Anacor Pharmaceuticals
-- Andor Pharmaceuticals
-- Angelini Pharma
-- AnGes MG
-- Anika Therapeutics
-- ANI Pharmaceuticals
-- Anji Pharma
-- Antares Pharma
-- Anteis
-- AntiOp
-- Apellis Pharmaceuticals
-- Aphria
-- AppianRx
-- Applied DNA Sciences
-- APR Applied Pharma Research
-- Aprecia Pharmaceuticals
-- Apricus Biosciences
-- Apsen Farmacutica
-- Aptar Pharma
-- Aquestive Therapeutics
-- Aralez Pharmaceuticals
-- Arbutus
-- Arcoral Pharma
-- Arcturus Therapeutics
-- Arecor
-- Argentum Pharmaceuticals
-- argenx
-- Aries Pharmaceuticals
-- Arisaph Pharmaceuticals
-- Armas Pharmaceuticals
-- Arsia Therapeutics
-- Artes Biotechnology
-- Art of Technology
-- Asahi Kasei
-- Asahi Kasei Kuraray Medica
-- Ascendia Pharmaceuticals
-- Ascend Therapeutics
-- Ascensia Diabetes Care
-- Asieris MediTech
-- Asklepios Biopharmaceutical
-- Aspen Global
-- Aspen Pharmacare Canada
-- Astellas Pharma
-- Astellas Pharma Europe
-- AstraZeneca
-- Athenex
-- Atlangram
-- Aucta Pharmaceuticals
-- Audentes Therapeutics
-- Aura Biosciences
-- Auris Medical
-- Aurora Cannabis
-- Auspherix
-- Austrianova Singapore
-- Autotelic
-- Auxilium Pharmaceuticals
-- Auxly Cannabis Group
-- and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/57aa2d
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
